Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H68T | ISIN: US6951271005 | Ticker-Symbol: 82P
Frankfurt
21.11.24
08:24 Uhr
16,100 Euro
+0,400
+2,55 %
1-Jahres-Chart
PACIRA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
PACIRA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,00016,30012:32
16,00016,30012:06

Aktuelle News zur PACIRA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.11.Pacira reports long-term relief in osteoarthritis gene therapy trial2
14.11.Pacira BioSciences: Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee88PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of...
► Artikel lesen
PACIRA BIOSCIENCES Aktie jetzt für 0€ handeln
07.11.Evaluating Pacira BioSciences: Insights From 8 Financial Analysts1
07.11.Royal Bank of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price2
07.11.Pacira Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary1
07.11.Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth-
07.11.Pacira BioSciences Non-GAAP EPS of $0.79 beats by $0.09, revenue of $168.6M misses by $9.43M2
06.11.Pacira BioSciences, Inc. - 10-Q, Quarterly Report-
06.11.Pacira BioSciences, Inc. - 8-K, Current Report-
30.10.Pacira BioSciences: Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 20242
21.10.Pacira BioSciences ernennt Shawn Cross zum CFO1
21.10.Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer70TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment...
► Artikel lesen
21.10.Pacira BioSciences, Inc. - 8-K, Current Report-
03.10.Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025114-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira...
► Artikel lesen
28.09.Executive reshuffles: NSC, PCRX and OMI Companies in focus2
27.09.Pacira BioSciences appoints Lauren Riker as interim CFO1
27.09.Pacira BioSciences, Inc. - 8-K, Current Report1
26.09.Pacira präsentiert neue Daten zur Gentherapie für Kniearthrose2
26.09.Pacira to present new gene therapy data for knee osteoarthritis1
26.09.Pacira BioSciences: Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee2
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1